Source comparison
CJC-1295 vs CJC-1295 no DAC & Ipamorelin: Research Application Comparison
Before selecting a peptide protocol, researchers must align mechanism with study design. The table below compares the three primary research approaches for growth hormone modulation. CJC-1295 with DAC GHRH analog with albumin binding; sustained GH elevation 6–
This comparison does not assign a generated winner or score.
- Before selecting a peptide protocol, researchers must align mechanism with study design. The table below compares the three primary research approaches for growth hormone modulation.
- CJC-1295 with DAC
- GHRH analog with albumin binding; sustained GH elevation
- 6–8 days
- Once weekly (1–2 mg)
- Long-term studies requiring stable IGF-1 elevation without daily dosing
- Best for sustained baseline elevation; less physiological than pulsatile mimicry
- CJC-1295 no DAC (Modified GRF 1-29)
- GHRH analog without albumin binding; amplifies natural GH pulses
- ~30 minutes
- 2–3 times daily (100–200 mcg)
- Studies examining pulsatile GH secretion or circadian rhythm effects
- Mimics natural physiology; requires precise timing relative to endogenous pulses
- Ipamorelin
- Ghrelin receptor agonist; stimulates GH release via GHS-R1a pathway
- ~2 hours
- 2–3 times daily (100–300 mcg), often combined with Modified GRF
- Synergistic protocols or research avoiding cortisol/prolactin elevation from older secretagogues
- Synergy with GHRH analogs; minimal off-target effects compared to GHRP-6 or hexarelin
- Modified GRF + Ipamorelin Combination
- Dual-pathway stimulation: GHRH receptor priming + ghrelin receptor activation
- Both clear within hours
- 2–3 times daily (100–200 mcg each peptide, dosed concurrently)
- Maximum pulsatile GH release in acute studies; circadian rhythm research
- 3–5× greater GH release than either alone; most closely mimics physiological secretion pattern